Predictors of switching antipsychotic medications in the treatment of schizophrenia

To identify patient characteristics and early changes in patients' clinical status that best predict subsequent switching of antipsychotic agents in the long-term treatment of schizophrenia. This post-hoc analysis used data from a one-year randomized, open-label, multisite study of antipsychoti...

Full description

Saved in:
Bibliographic Details
Published inBMC psychiatry Vol. 10; no. 1; p. 75
Main Authors Nyhuis, Allen W, Faries, Douglas E, Ascher-Svanum, Haya, Stauffer, Virginia L, Kinon, Bruce J
Format Journal Article
LanguageEnglish
Published England BioMed Central Ltd 28.09.2010
BioMed Central
BMC
Subjects
Online AccessGet full text

Cover

Loading…
Abstract To identify patient characteristics and early changes in patients' clinical status that best predict subsequent switching of antipsychotic agents in the long-term treatment of schizophrenia. This post-hoc analysis used data from a one-year randomized, open-label, multisite study of antipsychotics in the treatment of schizophrenia. The study protocol permitted switching of antipsychotics when clinically warranted after the first eight weeks. Baseline patient characteristics were assessed using standard psychiatric measures and reviews of medical records. The prediction model included baseline sociodemographics, comorbid psychiatric and non-psychiatric conditions, body weight, clinical and functional variables, as well as change scores on standard efficacy and tolerability measures during the first two weeks of treatment. Cox proportional hazards modeling was used to identify the best predictors of switching from the initially assigned antipsychotic medication. About one-third of patients (29.5%, 191/648) switched antipsychotics before the end of the one-year study. There were six variables identified as the best predictors of switching: lack of antipsychotic use in the prior year, pre-existing depression, female gender, lack of substance use disorder, worsening of akathisia (as measured by the Barnes Akathisia Scale), and worsening of symptoms of depression/anxiety (subscale score on the Positive and Negative Syndrome Scale) during the first two weeks of antipsychotic therapy. Switching antipsychotics appears to be prevalent in the naturalistic treatment of schizophrenia and can be predicted by a small and distinct set of variables. Interestingly, worsening of anxiety and depressive symptoms and of akathisia following two weeks of treatment were among the more robust predictors of subsequent switching of antipsychotics.
AbstractList To identify patient characteristics and early changes in patients' clinical status that best predict subsequent switching of antipsychotic agents in the long-term treatment of schizophrenia.BACKGROUNDTo identify patient characteristics and early changes in patients' clinical status that best predict subsequent switching of antipsychotic agents in the long-term treatment of schizophrenia.This post-hoc analysis used data from a one-year randomized, open-label, multisite study of antipsychotics in the treatment of schizophrenia. The study protocol permitted switching of antipsychotics when clinically warranted after the first eight weeks. Baseline patient characteristics were assessed using standard psychiatric measures and reviews of medical records. The prediction model included baseline sociodemographics, comorbid psychiatric and non-psychiatric conditions, body weight, clinical and functional variables, as well as change scores on standard efficacy and tolerability measures during the first two weeks of treatment. Cox proportional hazards modeling was used to identify the best predictors of switching from the initially assigned antipsychotic medication.METHODSThis post-hoc analysis used data from a one-year randomized, open-label, multisite study of antipsychotics in the treatment of schizophrenia. The study protocol permitted switching of antipsychotics when clinically warranted after the first eight weeks. Baseline patient characteristics were assessed using standard psychiatric measures and reviews of medical records. The prediction model included baseline sociodemographics, comorbid psychiatric and non-psychiatric conditions, body weight, clinical and functional variables, as well as change scores on standard efficacy and tolerability measures during the first two weeks of treatment. Cox proportional hazards modeling was used to identify the best predictors of switching from the initially assigned antipsychotic medication.About one-third of patients (29.5%, 191/648) switched antipsychotics before the end of the one-year study. There were six variables identified as the best predictors of switching: lack of antipsychotic use in the prior year, pre-existing depression, female gender, lack of substance use disorder, worsening of akathisia (as measured by the Barnes Akathisia Scale), and worsening of symptoms of depression/anxiety (subscale score on the Positive and Negative Syndrome Scale) during the first two weeks of antipsychotic therapy.RESULTSAbout one-third of patients (29.5%, 191/648) switched antipsychotics before the end of the one-year study. There were six variables identified as the best predictors of switching: lack of antipsychotic use in the prior year, pre-existing depression, female gender, lack of substance use disorder, worsening of akathisia (as measured by the Barnes Akathisia Scale), and worsening of symptoms of depression/anxiety (subscale score on the Positive and Negative Syndrome Scale) during the first two weeks of antipsychotic therapy.Switching antipsychotics appears to be prevalent in the naturalistic treatment of schizophrenia and can be predicted by a small and distinct set of variables. Interestingly, worsening of anxiety and depressive symptoms and of akathisia following two weeks of treatment were among the more robust predictors of subsequent switching of antipsychotics.CONCLUSIONSSwitching antipsychotics appears to be prevalent in the naturalistic treatment of schizophrenia and can be predicted by a small and distinct set of variables. Interestingly, worsening of anxiety and depressive symptoms and of akathisia following two weeks of treatment were among the more robust predictors of subsequent switching of antipsychotics.
Abstract Background To identify patient characteristics and early changes in patients' clinical status that best predict subsequent switching of antipsychotic agents in the long-term treatment of schizophrenia. Methods This post-hoc analysis used data from a one-year randomized, open-label, multisite study of antipsychotics in the treatment of schizophrenia. The study protocol permitted switching of antipsychotics when clinically warranted after the first eight weeks. Baseline patient characteristics were assessed using standard psychiatric measures and reviews of medical records. The prediction model included baseline sociodemographics, comorbid psychiatric and non-psychiatric conditions, body weight, clinical and functional variables, as well as change scores on standard efficacy and tolerability measures during the first two weeks of treatment. Cox proportional hazards modeling was used to identify the best predictors of switching from the initially assigned antipsychotic medication. Results About one-third of patients (29.5%, 191/648) switched antipsychotics before the end of the one-year study. There were six variables identified as the best predictors of switching: lack of antipsychotic use in the prior year, pre-existing depression, female gender, lack of substance use disorder, worsening of akathisia (as measured by the Barnes Akathisia Scale), and worsening of symptoms of depression/anxiety (subscale score on the Positive and Negative Syndrome Scale) during the first two weeks of antipsychotic therapy. Conclusions Switching antipsychotics appears to be prevalent in the naturalistic treatment of schizophrenia and can be predicted by a small and distinct set of variables. Interestingly, worsening of anxiety and depressive symptoms and of akathisia following two weeks of treatment were among the more robust predictors of subsequent switching of antipsychotics.
To identify patient characteristics and early changes in patients' clinical status that best predict subsequent switching of antipsychotic agents in the long-term treatment of schizophrenia. This post-hoc analysis used data from a one-year randomized, open-label, multisite study of antipsychotics in the treatment of schizophrenia. The study protocol permitted switching of antipsychotics when clinically warranted after the first eight weeks. Baseline patient characteristics were assessed using standard psychiatric measures and reviews of medical records. The prediction model included baseline sociodemographics, comorbid psychiatric and non-psychiatric conditions, body weight, clinical and functional variables, as well as change scores on standard efficacy and tolerability measures during the first two weeks of treatment. Cox proportional hazards modeling was used to identify the best predictors of switching from the initially assigned antipsychotic medication. About one-third of patients (29.5%, 191/648) switched antipsychotics before the end of the one-year study. There were six variables identified as the best predictors of switching: lack of antipsychotic use in the prior year, pre-existing depression, female gender, lack of substance use disorder, worsening of akathisia (as measured by the Barnes Akathisia Scale), and worsening of symptoms of depression/anxiety (subscale score on the Positive and Negative Syndrome Scale) during the first two weeks of antipsychotic therapy. Switching antipsychotics appears to be prevalent in the naturalistic treatment of schizophrenia and can be predicted by a small and distinct set of variables. Interestingly, worsening of anxiety and depressive symptoms and of akathisia following two weeks of treatment were among the more robust predictors of subsequent switching of antipsychotics.
To identify patient characteristics and early changes in patients' clinical status that best predict subsequent switching of antipsychotic agents in the long-term treatment of schizophrenia. This post-hoc analysis used data from a one-year randomized, open-label, multisite study of antipsychotics in the treatment of schizophrenia. The study protocol permitted switching of antipsychotics when clinically warranted after the first eight weeks. Baseline patient characteristics were assessed using standard psychiatric measures and reviews of medical records. The prediction model included baseline sociodemographics, comorbid psychiatric and non-psychiatric conditions, body weight, clinical and functional variables, as well as change scores on standard efficacy and tolerability measures during the first two weeks of treatment. Cox proportional hazards modeling was used to identify the best predictors of switching from the initially assigned antipsychotic medication. About one-third of patients (29.5%, 191/648) switched antipsychotics before the end of the one-year study. There were six variables identified as the best predictors of switching: lack of antipsychotic use in the prior year, pre-existing depression, female gender, lack of substance use disorder, worsening of akathisia (as measured by the Barnes Akathisia Scale), and worsening of symptoms of depression/anxiety (subscale score on the Positive and Negative Syndrome Scale) during the first two weeks of antipsychotic therapy. Switching antipsychotics appears to be prevalent in the naturalistic treatment of schizophrenia and can be predicted by a small and distinct set of variables. Interestingly, worsening of anxiety and depressive symptoms and of akathisia following two weeks of treatment were among the more robust predictors of subsequent switching of antipsychotics.
Background To identify patient characteristics and early changes in patients' clinical status that best predict subsequent switching of antipsychotic agents in the long-term treatment of schizophrenia. Methods This post-hoc analysis used data from a one-year randomized, open-label, multisite study of antipsychotics in the treatment of schizophrenia. The study protocol permitted switching of antipsychotics when clinically warranted after the first eight weeks. Baseline patient characteristics were assessed using standard psychiatric measures and reviews of medical records. The prediction model included baseline sociodemographics, comorbid psychiatric and non-psychiatric conditions, body weight, clinical and functional variables, as well as change scores on standard efficacy and tolerability measures during the first two weeks of treatment. Cox proportional hazards modeling was used to identify the best predictors of switching from the initially assigned antipsychotic medication. Results About one-third of patients (29.5%, 191/648) switched antipsychotics before the end of the one-year study. There were six variables identified as the best predictors of switching: lack of antipsychotic use in the prior year, pre-existing depression, female gender, lack of substance use disorder, worsening of akathisia (as measured by the Barnes Akathisia Scale), and worsening of symptoms of depression/anxiety (subscale score on the Positive and Negative Syndrome Scale) during the first two weeks of antipsychotic therapy. Conclusions Switching antipsychotics appears to be prevalent in the naturalistic treatment of schizophrenia and can be predicted by a small and distinct set of variables. Interestingly, worsening of anxiety and depressive symptoms and of akathisia following two weeks of treatment were among the more robust predictors of subsequent switching of antipsychotics.
ArticleNumber 75
Audience Academic
Author Ascher-Svanum, Haya
Nyhuis, Allen W
Stauffer, Virginia L
Faries, Douglas E
Kinon, Bruce J
AuthorAffiliation 1 Eli Lilly and Company, Indianapolis, IN USA
AuthorAffiliation_xml – name: 1 Eli Lilly and Company, Indianapolis, IN USA
Author_xml – sequence: 1
  givenname: Allen W
  surname: Nyhuis
  fullname: Nyhuis, Allen W
– sequence: 2
  givenname: Douglas E
  surname: Faries
  fullname: Faries, Douglas E
– sequence: 3
  givenname: Haya
  surname: Ascher-Svanum
  fullname: Ascher-Svanum, Haya
– sequence: 4
  givenname: Virginia L
  surname: Stauffer
  fullname: Stauffer, Virginia L
– sequence: 5
  givenname: Bruce J
  surname: Kinon
  fullname: Kinon, Bruce J
BackLink https://www.ncbi.nlm.nih.gov/pubmed/20920179$$D View this record in MEDLINE/PubMed
BookMark eNqFUl1rFDEUHaRiP_TZNxn0wadpk8nk60Voix-FgoIKvoVM5mY3y2yyJlml_nozu3XplhbJw2Ruzjmce-49rg588FBVLzE6xViwM9xx3LRd96PBqOH0SXW0qxzcuR9WxyktEMJcUPysOmyRbMuPPKq-fokwOJNDTHWwdfrtspk7P6u1z26Vbsw8ZGfq5QTS2QWfaufrPIc6R9B5CT5veIX0J6zmEbzTz6unVo8JXtx-T6rvH95_u_zUXH_-eHV5ft30rCO5YYYTYBwRoHbAbWcxIDJAjzttoUeIAQPSa8Kt4Mj0RHBgeEAIQA9ADCYn1dVWdwh6oVbRLXW8UUE7tSmEOFM6FvcjKA3MWsEQsUZ0gvVaciF1LxmScuC2K1rvtlqrdV-aNaWvqMc90f0X7-ZqFn6pVlLKyGTmYivQu_CIwP6LCUs1DUhNA1IYKU6LyNtbFzH8XEPKaumSgXHUHsI6KUk7KnFL8X-RnApBCKGoIF_fQy7COvoyGCVRiwXv6NT-my1opktazttQPJpJUp23RLZSMNkW1OkDqHIGWDpTNtO6Ut8jvLqb6i6Nf_tXAGdbgIkhpQh2BymBTBv-QET0HsO4vNnM4sWNj_L-AlIh_6M
CitedBy_id crossref_primary_10_1155_2011_317368
crossref_primary_10_1517_14656566_2014_884071
crossref_primary_10_1177_1039856218810166
crossref_primary_10_1186_1471_244X_13_248
crossref_primary_10_1016_j_schres_2020_12_006
crossref_primary_10_18553_jmcp_2024_23319
crossref_primary_10_1016_j_heliyon_2024_e39792
crossref_primary_10_1097_YIC_0000000000000296
crossref_primary_10_1177_2045125312453935
crossref_primary_10_1186_1471_244X_13_221
crossref_primary_10_1016_j_schres_2015_10_040
crossref_primary_10_1097_YIC_0000000000000372
crossref_primary_10_1016_j_psychres_2013_07_030
crossref_primary_10_1089_cap_2010_0095
crossref_primary_10_16946_kjsr_2017_20_2_69
crossref_primary_10_1016_S2215_0366_23_00262_6
crossref_primary_10_1016_j_rpsmen_2011_07_001
crossref_primary_10_1111_papt_12265
crossref_primary_10_1186_s12991_023_00472_z
crossref_primary_10_2147_NDT_S358392
crossref_primary_10_1007_s40263_015_0282_7
crossref_primary_10_2190_PM_45_2_c
crossref_primary_10_3390_ijerph20054376
crossref_primary_10_1016_j_encep_2017_02_007
crossref_primary_10_1016_j_schres_2021_11_020
crossref_primary_10_1177_0269881112463469
crossref_primary_10_1017_S1092852918001086
crossref_primary_10_1186_1744_859X_12_1
crossref_primary_10_1097_YIC_0000000000000068
crossref_primary_10_1186_1471_244X_14_53
crossref_primary_10_1186_s12888_016_0879_5
crossref_primary_10_1177_0706743717718166
crossref_primary_10_3390_jcm11195965
crossref_primary_10_17826_cumj_903054
crossref_primary_10_1016_j_rpsm_2011_07_003
Cites_doi 10.1093/schbul/sbm134
10.1016/S0920-9964(01)00326-7
10.1111/j.1524-4733.2006.00083.x
10.1176/appi.ajp.160.11.2063
10.1176/appi.ajp.159.9.1534
10.1176/ajp.2006.163.4.611
10.4088/JCP.v68n0301
10.1192/bjp.154.5.672
10.1093/schbul/13.2.261
10.1186/1471-244X-6-8
10.1192/bjp.184.4.346
10.1176/appi.ps.52.6.805
10.1185/030079907X162665
10.1192/bjp.191.50.s64
10.1093/schbul/21.3.419
10.1176/ajp.142.4.499
10.1001/archpsyc.59.10.877
10.1186/1471-244X-9-54
10.1001/jama.290.12.1624
10.1177/0269881105058978
10.4088/JCP.v64n0514
10.1056/NEJMoa051688
10.1186/1741-7015-3-21
10.1097/01.jcp.0000245562.99036.92
10.4088/JCP.v65n0812
10.1001/archpsyc.1976.01770060086012
10.1093/schbul/sbm161
10.1111/j.1600-0447.1970.tb02066.x
10.4088/JCP.v67n0317
10.1176/appi.ps.54.10.1407
10.1176/ajp.2007.164.3.415
10.1016/j.biopsych.2005.02.023
10.1097/JCP.0b013e318185e74a
10.1016/0149-7189(88)90033-X
10.1097/00005650-199206000-00002
10.1176/ajp.2006.163.4.600
10.4088/JCP.v67n0715
10.1002/hup.325
10.1097/00004714-200206000-00003
10.2466/pr0.1962.10.3.799
10.1007/BF02287330
10.1136/bmj.321.7273.1360
10.4088/JCP.v62n1003
10.1192/bjp.187.2.137
10.1001/archpsyc.60.12.1228
10.1177/0269881105056668
10.1016/j.schres.2009.04.018
ContentType Journal Article
Copyright COPYRIGHT 2010 BioMed Central Ltd.
2010 Nyhuis et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Copyright ©2010 Nyhuis et al; licensee BioMed Central Ltd. 2010 Nyhuis et al; licensee BioMed Central Ltd.
Copyright_xml – notice: COPYRIGHT 2010 BioMed Central Ltd.
– notice: 2010 Nyhuis et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
– notice: Copyright ©2010 Nyhuis et al; licensee BioMed Central Ltd. 2010 Nyhuis et al; licensee BioMed Central Ltd.
DBID AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
3V.
7TK
7X7
7XB
88E
88G
8FI
8FJ
8FK
ABUWG
AFKRA
AZQEC
BENPR
CCPQU
DWQXO
FYUFA
GHDGH
GNUQQ
K9.
M0S
M1P
M2M
PHGZM
PHGZT
PIMPY
PJZUB
PKEHL
PPXIY
PQEST
PQQKQ
PQUKI
PRINS
PSYQQ
Q9U
7X8
5PM
DOA
DOI 10.1186/1471-244X-10-75
DatabaseName CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
ProQuest Central (Corporate)
Neurosciences Abstracts
Health & Medical Collection
ProQuest Central (purchase pre-March 2016)
Medical Database (Alumni Edition)
Psychology Database (Alumni)
Hospital Premium Collection
Hospital Premium Collection (Alumni Edition)
ProQuest Central (Alumni) (purchase pre-March 2016)
ProQuest Central (Alumni)
ProQuest Central UK/Ireland
ProQuest Central Essentials
ProQuest Central
ProQuest One Community College
ProQuest Central Korea
Health Research Premium Collection
Health Research Premium Collection (Alumni)
ProQuest Central Student
ProQuest Health & Medical Complete (Alumni)
Health & Medical Collection (Alumni)
Medical Database
Psychology Database
ProQuest Central Premium
ProQuest One Academic
Publicly Available Content Database
ProQuest Health & Medical Research Collection
ProQuest One Academic Middle East (New)
ProQuest One Health & Nursing
ProQuest One Academic Eastern Edition (DO NOT USE)
ProQuest One Academic
ProQuest One Academic UKI Edition
ProQuest Central China
ProQuest One Psychology
ProQuest Central Basic
MEDLINE - Academic
PubMed Central (Full Participant titles)
DOAJ Directory of Open Access Journals
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
Publicly Available Content Database
ProQuest One Psychology
ProQuest Central Student
ProQuest One Academic Middle East (New)
ProQuest Central Essentials
ProQuest Health & Medical Complete (Alumni)
ProQuest Central (Alumni Edition)
ProQuest One Community College
ProQuest One Health & Nursing
ProQuest Central China
ProQuest Central
Health Research Premium Collection
Health and Medicine Complete (Alumni Edition)
ProQuest Central Korea
Health & Medical Research Collection
ProQuest Central (New)
ProQuest Medical Library (Alumni)
ProQuest Central Basic
ProQuest One Academic Eastern Edition
ProQuest Hospital Collection
Health Research Premium Collection (Alumni)
ProQuest Psychology Journals (Alumni)
Neurosciences Abstracts
ProQuest Hospital Collection (Alumni)
ProQuest Health & Medical Complete
ProQuest Medical Library
ProQuest Psychology Journals
ProQuest One Academic UKI Edition
ProQuest One Academic
ProQuest One Academic (New)
ProQuest Central (Alumni)
MEDLINE - Academic
DatabaseTitleList MEDLINE - Academic

Publicly Available Content Database
Neurosciences Abstracts
MEDLINE



Database_xml – sequence: 1
  dbid: DOA
  name: DOAJ Directory of Open Access Journals
  url: https://www.doaj.org/
  sourceTypes: Open Website
– sequence: 2
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 3
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
– sequence: 4
  dbid: BENPR
  name: ProQuest Central
  url: https://www.proquest.com/central
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 1471-244X
EndPage 75
ExternalDocumentID oai_doaj_org_article_ae6ff8603fc8486ba9789ab96099d7f4
PMC2955631
oai_biomedcentral_com_1471_244X_10_75
2502954941
A239298692
20920179
10_1186_1471_244X_10_75
Genre Research Support, Non-U.S. Gov't
Journal Article
Comparative Study
GeographicLocations United States
GeographicLocations_xml – name: United States
GroupedDBID ---
0R~
23N
2VQ
2WC
4.4
53G
5VS
6J9
7X7
88E
8FI
8FJ
AAFWJ
AAJSJ
AASML
AAYXX
ABDBF
ABIVO
ABUWG
ACGFO
ACGFS
ACIHN
ACPRK
ACUHS
ADBBV
ADRAZ
ADUKV
AEAQA
AENEX
AFKRA
AFPKN
AHBYD
AHMBA
AHSBF
AHYZX
ALIPV
ALMA_UNASSIGNED_HOLDINGS
AMKLP
AMTXH
AOIJS
AZQEC
BAPOH
BAWUL
BCNDV
BENPR
BFQNJ
BMC
BPHCQ
BVXVI
C1A
C6C
CCPQU
CITATION
CS3
DIK
DWQXO
E3Z
EAD
EAP
EAS
EBD
EBLON
EBS
EJD
EMB
EMK
EMOBN
ESX
F5P
FYUFA
GNUQQ
GROUPED_DOAJ
GX1
H13
HMCUK
HYE
IAO
IHR
INH
INR
IPNFZ
IPY
ITC
KQ8
M1P
M2M
M48
M~E
O5R
O5S
OK1
OVT
P2P
PGMZT
PHGZM
PHGZT
PIMPY
PQQKQ
PROAC
PSQYO
PSYQQ
RBZ
RIG
RNS
ROL
RPM
RSV
SMD
SOJ
SV3
TR2
TUS
UKHRP
W2D
WOQ
WOW
XSB
-A0
3V.
ACRMQ
ADINQ
C24
CGR
CUY
CVF
ECM
EIF
NPM
PMFND
7TK
7XB
8FK
K9.
PJZUB
PKEHL
PPXIY
PQEST
PQUKI
PRINS
Q9U
7X8
ABVAZ
AFGXO
AFNRJ
5PM
PUEGO
ID FETCH-LOGICAL-b643t-6c73e6703e5fd124f1e03deb14afeb006e6e3ba37f870cb387e61d00eeade3c13
IEDL.DBID RBZ
ISSN 1471-244X
IngestDate Wed Aug 27 00:32:06 EDT 2025
Thu Aug 21 18:13:01 EDT 2025
Wed May 22 07:10:24 EDT 2024
Fri Jul 11 03:53:33 EDT 2025
Fri Jul 11 09:02:46 EDT 2025
Fri Jul 25 04:28:19 EDT 2025
Tue Jun 17 21:19:16 EDT 2025
Tue Jun 10 20:13:47 EDT 2025
Thu Jan 02 22:06:26 EST 2025
Thu Apr 24 22:57:31 EDT 2025
Tue Jul 01 01:46:14 EDT 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 1
Language English
License This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-b643t-6c73e6703e5fd124f1e03deb14afeb006e6e3ba37f870cb387e61d00eeade3c13
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
ObjectType-Article-2
ObjectType-Feature-1
content type line 23
OpenAccessLink http://dx.doi.org/10.1186/1471-244X-10-75
PMID 20920179
PQID 902187454
PQPubID 44775
PageCount 1
ParticipantIDs doaj_primary_oai_doaj_org_article_ae6ff8603fc8486ba9789ab96099d7f4
pubmedcentral_primary_oai_pubmedcentral_nih_gov_2955631
biomedcentral_primary_oai_biomedcentral_com_1471_244X_10_75
proquest_miscellaneous_954591251
proquest_miscellaneous_758833350
proquest_journals_902187454
gale_infotracmisc_A239298692
gale_infotracacademiconefile_A239298692
pubmed_primary_20920179
crossref_primary_10_1186_1471_244X_10_75
crossref_citationtrail_10_1186_1471_244X_10_75
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2010-09-28
PublicationDateYYYYMMDD 2010-09-28
PublicationDate_xml – month: 09
  year: 2010
  text: 2010-09-28
  day: 28
PublicationDecade 2010
PublicationPlace England
PublicationPlace_xml – name: England
– name: London
PublicationTitle BMC psychiatry
PublicationTitleAlternate BMC Psychiatry
PublicationYear 2010
Publisher BioMed Central Ltd
BioMed Central
BMC
Publisher_xml – name: BioMed Central Ltd
– name: BioMed Central
– name: BMC
References J Endicott (705_CR29) 1976; 33
MJ Sernyak (705_CR12) 2005; 32
TS Stroup (705_CR7) 2007; 164
JP McEvoy (705_CR4) 2006; 163
TS Stroup (705_CR6) 2006; 163
O Agid (705_CR20) 2003; 60
H Ascher-Svanum (705_CR48) 2006; 6
WW Fleischhacker (705_CR45) 1994; 382
HY Meltzer (705_CR50) 2003; 59
LA Lindamer (705_CR37) 2003; 54
HC Kraemer (705_CR32) 2002; 59
PJ Weiden (705_CR35) 1995; 21
JE Overall (705_CR19) 1962; 10
H Ascher-Svanum (705_CR39) 2006; 67
BL Svarstad (705_CR38) 2001; 52
JM Davis (705_CR26) 2001; 62
H Ascher-Svanum (705_CR21) 2008; 34
DA Smelson (705_CR14) 2006; 26
CU Correll (705_CR22) 2003; 160
RE Drake (705_CR42) 1985; 142
MR Dossenbach (705_CR3) 2001; 62
HC Margolese (705_CR44) 2001; 101
PJ Weiden (705_CR8) 2003; 64
S Kapur (705_CR46) 2000; 321
SR Kay (705_CR25) 1987; 13
TR Barnes (705_CR30) 1989; 154
PJ Weiden (705_CR9) 2006; 20
DL Leslie (705_CR34) 2002; 159
S Hamer (705_CR1) 2007; 50
S Leucht (705_CR24) 2007; 68
JE Ware Jr (705_CR28) 1992; 30
SL Tunis (705_CR17) 2006; 9
H Liu-Seifert (705_CR11) 2005; 3
R Miller (705_CR51) 2009; 113
H Ascher-Svanum (705_CR47) 2005; 19
JA Lieberman (705_CR2) 2005; 353
GM Simpson (705_CR31) 1970; 212
S Almond (705_CR33) 2004; 184
AF Lehman (705_CR27) 1988; 11
SL Tunis (705_CR18) 2007; 23
SR Tunis (705_CR16) 2003; 290
H Ascher-Svanum (705_CR36) 2006; 67
P Czobor (705_CR49) 2002; 22
S Leucht (705_CR23) 2005; 57
S Park (705_CR5) 2005; 187
S Weinmann (705_CR13) 2004; 65
PJ Weiden (705_CR10) 2007; 68
BJ Kinon (705_CR40) 2008; 28
L Hansen (705_CR43) 2001; 16
DE Faries (705_CR15) 2009; 9
J Rabinowitz (705_CR41) 2008; 34
16649833 - J Clin Psychiatry. 2006 Mar;67(3):453-60
12006893 - J Clin Psychopharmacol. 2002 Jun;22(3):244-51
14506122 - JAMA. 2003 Sep 24;290(12):1624-32
19481424 - Schizophr Res. 2009 Sep;113(2-3):138-44
15632800 - J Behav Health Serv Res. 2005 Jan-Mar;32(1):85-94
16585434 - Am J Psychiatry. 2006 Apr;163(4):600-10
17110828 - J Clin Psychopharmacol. 2006 Dec;26(6):666-7
16375765 - BMC Med. 2005;3:21
15953491 - Biol Psychiatry. 2005 Jun 15;57(12):1543-9
11099266 - BMJ. 2000 Dec 2;321(7273):1360-1
7916523 - Acta Psychiatr Scand Suppl. 1994;382:11-5
2574607 - Br J Psychiatry. 1989 May;154:672-6
1593914 - Med Care. 1992 Jun;30(6):473-83
12413638 - Schizophr Res. 2003 Jan 1;59(1):19-27
18794651 - J Clin Psychopharmacol. 2008 Oct;28(5):544-9
16585435 - Am J Psychiatry. 2006 Apr;163(4):611-22
938196 - Arch Gen Psychiatry. 1976 Jun;33(6):766-71
16172203 - N Engl J Med. 2005 Sep 22;353(12):1209-23
16280344 - J Psychopharmacol. 2005 Nov;19(6 Suppl):110-7
16204323 - J Psychopharmacol. 2006 Jan;20(1):104-18
12404546 - Hum Psychopharmacol. 2001 Oct;16(7):495-505
14662555 - Arch Gen Psychiatry. 2003 Dec;60(12):1228-35
11816864 - J Clin Psychiatry. 2001 Oct;62(10):757-71
15056580 - Br J Psychiatry. 2004 Apr;184:346-51
3616518 - Schizophr Bull. 1987;13(2):261-76
16504026 - BMC Psychiatry. 2006;6:8
18156640 - Schizophr Bull. 2008 Nov;34(6):1163-71
15323596 - J Clin Psychiatry. 2004 Aug;65(8):1099-105
12202274 - Am J Psychiatry. 2002 Sep;159(9):1534-40
12365874 - Arch Gen Psychiatry. 2002 Oct;59(10):877-83
17539698 - J Clin Psychiatry. 2007;68 Suppl 4:34-9
7481573 - Schizophr Bull. 1995;21(3):419-29
11376229 - Psychiatr Serv. 2001 Jun;52(6):805-11
16889456 - J Clin Psychiatry. 2006 Jul;67(7):1114-23
17257471 - Curr Med Res Opin. 2007 Jan;23(1):97-104
19725969 - BMC Psychiatry. 2009;9:54
4917967 - Acta Psychiatr Scand Suppl. 1970;212:11-9
16055824 - Br J Psychiatry. 2005 Aug;187:137-42
12755663 - J Clin Psychiatry. 2003 May;64(5):580-8
3976927 - Am J Psychiatry. 1985 Apr;142(4):499-501
17329466 - Am J Psychiatry. 2007 Mar;164(3):415-27
14594760 - Am J Psychiatry. 2003 Nov;160(11):2063-5
14557530 - Psychiatr Serv. 2003 Oct;54(10):1407-9
17388703 - J Clin Psychiatry. 2007 Mar;68(3):352-60
11232749 - J Clin Psychiatry. 2001;62 Suppl 2:28-34
18019047 - Br J Psychiatry Suppl. 2007 Aug;50:s64-70
18212325 - Schizophr Bull. 2008 Mar;34(2):286-91
16626411 - Value Health. 2006 Mar-Apr;9(2):77-89
References_xml – volume: 34
  start-page: 1163
  issue: 6
  year: 2008
  ident: 705_CR21
  publication-title: Schizophr Bull
  doi: 10.1093/schbul/sbm134
– volume: 59
  start-page: 19
  issue: 1
  year: 2003
  ident: 705_CR50
  publication-title: Schizophr Res
  doi: 10.1016/S0920-9964(01)00326-7
– volume: 9
  start-page: 77
  issue: 2
  year: 2006
  ident: 705_CR17
  publication-title: Value Health
  doi: 10.1111/j.1524-4733.2006.00083.x
– volume: 101
  start-page: 128
  year: 2001
  ident: 705_CR44
  publication-title: Acta Psychiatr Belg
– volume: 160
  start-page: 2063
  issue: 11
  year: 2003
  ident: 705_CR22
  publication-title: Am J Psychiatry
  doi: 10.1176/appi.ajp.160.11.2063
– volume: 159
  start-page: 1534
  issue: 9
  year: 2002
  ident: 705_CR34
  publication-title: Am J Psychiatry
  doi: 10.1176/appi.ajp.159.9.1534
– volume: 68
  start-page: 34
  issue: Suppl 4
  year: 2007
  ident: 705_CR10
  publication-title: J Clin Psychiatry
– volume: 163
  start-page: 611
  issue: 4
  year: 2006
  ident: 705_CR6
  publication-title: Am J Psychiatry
  doi: 10.1176/ajp.2006.163.4.611
– volume: 68
  start-page: 352
  issue: 3
  year: 2007
  ident: 705_CR24
  publication-title: J Clin Psychiatry
  doi: 10.4088/JCP.v68n0301
– volume: 154
  start-page: 672
  year: 1989
  ident: 705_CR30
  publication-title: Br J Psychiatry
  doi: 10.1192/bjp.154.5.672
– volume: 13
  start-page: 261
  issue: 2
  year: 1987
  ident: 705_CR25
  publication-title: Schizophr Bull
  doi: 10.1093/schbul/13.2.261
– volume: 6
  start-page: 8
  year: 2006
  ident: 705_CR48
  publication-title: BMC Psychiatry
  doi: 10.1186/1471-244X-6-8
– volume: 184
  start-page: 346
  year: 2004
  ident: 705_CR33
  publication-title: Br J Psychiatry
  doi: 10.1192/bjp.184.4.346
– volume: 52
  start-page: 805
  issue: 6
  year: 2001
  ident: 705_CR38
  publication-title: Psychiatr Serv
  doi: 10.1176/appi.ps.52.6.805
– volume: 23
  start-page: 97
  issue: 1
  year: 2007
  ident: 705_CR18
  publication-title: Curr Med Res Opin
  doi: 10.1185/030079907X162665
– volume: 382
  start-page: 11
  year: 1994
  ident: 705_CR45
  publication-title: Acta Psychiatr Scand
– volume: 50
  start-page: s64
  year: 2007
  ident: 705_CR1
  publication-title: Br J Psychiatry Suppl
  doi: 10.1192/bjp.191.50.s64
– volume: 21
  start-page: 419
  issue: 3
  year: 1995
  ident: 705_CR35
  publication-title: Schizophr Bull
  doi: 10.1093/schbul/21.3.419
– volume: 142
  start-page: 499
  issue: 4
  year: 1985
  ident: 705_CR42
  publication-title: Am J Psychiatry
  doi: 10.1176/ajp.142.4.499
– volume: 59
  start-page: 877
  issue: 10
  year: 2002
  ident: 705_CR32
  publication-title: Arch Gen Psychiatry
  doi: 10.1001/archpsyc.59.10.877
– volume: 9
  start-page: 54
  year: 2009
  ident: 705_CR15
  publication-title: BMC Psychiatry
  doi: 10.1186/1471-244X-9-54
– volume: 290
  start-page: 1624
  issue: 12
  year: 2003
  ident: 705_CR16
  publication-title: J Am Med Assoc
  doi: 10.1001/jama.290.12.1624
– volume: 19
  start-page: 110
  issue: 6 Suppl
  year: 2005
  ident: 705_CR47
  publication-title: J Psychopharmacol
  doi: 10.1177/0269881105058978
– volume: 64
  start-page: 580
  issue: 5
  year: 2003
  ident: 705_CR8
  publication-title: J Clin Psychiatry
  doi: 10.4088/JCP.v64n0514
– volume: 353
  start-page: 1209
  issue: 12
  year: 2005
  ident: 705_CR2
  publication-title: N Engl J Med
  doi: 10.1056/NEJMoa051688
– volume: 3
  start-page: 21
  year: 2005
  ident: 705_CR11
  publication-title: BMC Med
  doi: 10.1186/1741-7015-3-21
– volume: 26
  start-page: 666
  issue: 6
  year: 2006
  ident: 705_CR14
  publication-title: J Clin Psychopharmacol
  doi: 10.1097/01.jcp.0000245562.99036.92
– volume: 65
  start-page: 1099
  issue: 8
  year: 2004
  ident: 705_CR13
  publication-title: J Clin Psychiatry
  doi: 10.4088/JCP.v65n0812
– volume: 33
  start-page: 766
  issue: 6
  year: 1976
  ident: 705_CR29
  publication-title: Arch Gen Psychiatry
  doi: 10.1001/archpsyc.1976.01770060086012
– volume: 34
  start-page: 286
  issue: 2
  year: 2008
  ident: 705_CR41
  publication-title: Schizophr Bull
  doi: 10.1093/schbul/sbm161
– volume: 212
  start-page: 11
  year: 1970
  ident: 705_CR31
  publication-title: Acta Psychiatr Scand Suppl
  doi: 10.1111/j.1600-0447.1970.tb02066.x
– volume: 67
  start-page: 453
  issue: 3
  year: 2006
  ident: 705_CR36
  publication-title: J Clin Psychiatry
  doi: 10.4088/JCP.v67n0317
– volume: 62
  start-page: 28
  issue: Suppl 2
  year: 2001
  ident: 705_CR3
  publication-title: J Clin Psychiatry
– volume: 54
  start-page: 1407
  issue: 10
  year: 2003
  ident: 705_CR37
  publication-title: Psychiatr Serv
  doi: 10.1176/appi.ps.54.10.1407
– volume: 164
  start-page: 415
  issue: 3
  year: 2007
  ident: 705_CR7
  publication-title: Am J Psychiatry
  doi: 10.1176/ajp.2007.164.3.415
– volume: 57
  start-page: 1543
  issue: 12
  year: 2005
  ident: 705_CR23
  publication-title: Biol Psychiatry
  doi: 10.1016/j.biopsych.2005.02.023
– volume: 28
  start-page: 544
  issue: 5
  year: 2008
  ident: 705_CR40
  publication-title: J Clin Psychopharmacol
  doi: 10.1097/JCP.0b013e318185e74a
– volume: 11
  start-page: 51
  issue: 4
  year: 1988
  ident: 705_CR27
  publication-title: Eval Program Plann
  doi: 10.1016/0149-7189(88)90033-X
– volume: 30
  start-page: 473
  issue: 6
  year: 1992
  ident: 705_CR28
  publication-title: Med Care
  doi: 10.1097/00005650-199206000-00002
– volume: 163
  start-page: 600
  issue: 4
  year: 2006
  ident: 705_CR4
  publication-title: Am J Psychiatry
  doi: 10.1176/ajp.2006.163.4.600
– volume: 67
  start-page: 1114
  issue: 7
  year: 2006
  ident: 705_CR39
  publication-title: J Clin Psychiatry
  doi: 10.4088/JCP.v67n0715
– volume: 16
  start-page: 495
  issue: 7
  year: 2001
  ident: 705_CR43
  publication-title: Hum Psychopharmacol
  doi: 10.1002/hup.325
– volume: 22
  start-page: 244
  issue: 3
  year: 2002
  ident: 705_CR49
  publication-title: J Clin Psychopharmacol
  doi: 10.1097/00004714-200206000-00003
– volume: 10
  start-page: 799
  year: 1962
  ident: 705_CR19
  publication-title: Psychol Rep
  doi: 10.2466/pr0.1962.10.3.799
– volume: 32
  start-page: 85
  issue: 1
  year: 2005
  ident: 705_CR12
  publication-title: J Behav Health Serv Res
  doi: 10.1007/BF02287330
– volume: 321
  start-page: 1360
  issue: 7273
  year: 2000
  ident: 705_CR46
  publication-title: BMJ
  doi: 10.1136/bmj.321.7273.1360
– volume: 62
  start-page: 757
  issue: 10
  year: 2001
  ident: 705_CR26
  publication-title: J Clin Psychiatry
  doi: 10.4088/JCP.v62n1003
– volume: 187
  start-page: 137
  year: 2005
  ident: 705_CR5
  publication-title: Br J Psychiatry
  doi: 10.1192/bjp.187.2.137
– volume: 60
  start-page: 1228
  issue: 12
  year: 2003
  ident: 705_CR20
  publication-title: Arch Gen Psychiatry
  doi: 10.1001/archpsyc.60.12.1228
– volume: 20
  start-page: 104
  issue: 1
  year: 2006
  ident: 705_CR9
  publication-title: J Psychopharmacol
  doi: 10.1177/0269881105056668
– volume: 113
  start-page: 138
  issue: 2-3
  year: 2009
  ident: 705_CR51
  publication-title: Schizophr Res
  doi: 10.1016/j.schres.2009.04.018
– reference: 16504026 - BMC Psychiatry. 2006;6:8
– reference: 16280344 - J Psychopharmacol. 2005 Nov;19(6 Suppl):110-7
– reference: 14662555 - Arch Gen Psychiatry. 2003 Dec;60(12):1228-35
– reference: 12202274 - Am J Psychiatry. 2002 Sep;159(9):1534-40
– reference: 17388703 - J Clin Psychiatry. 2007 Mar;68(3):352-60
– reference: 18212325 - Schizophr Bull. 2008 Mar;34(2):286-91
– reference: 3976927 - Am J Psychiatry. 1985 Apr;142(4):499-501
– reference: 938196 - Arch Gen Psychiatry. 1976 Jun;33(6):766-71
– reference: 15323596 - J Clin Psychiatry. 2004 Aug;65(8):1099-105
– reference: 7481573 - Schizophr Bull. 1995;21(3):419-29
– reference: 12755663 - J Clin Psychiatry. 2003 May;64(5):580-8
– reference: 15056580 - Br J Psychiatry. 2004 Apr;184:346-51
– reference: 17257471 - Curr Med Res Opin. 2007 Jan;23(1):97-104
– reference: 19481424 - Schizophr Res. 2009 Sep;113(2-3):138-44
– reference: 11376229 - Psychiatr Serv. 2001 Jun;52(6):805-11
– reference: 12006893 - J Clin Psychopharmacol. 2002 Jun;22(3):244-51
– reference: 14594760 - Am J Psychiatry. 2003 Nov;160(11):2063-5
– reference: 11099266 - BMJ. 2000 Dec 2;321(7273):1360-1
– reference: 17110828 - J Clin Psychopharmacol. 2006 Dec;26(6):666-7
– reference: 1593914 - Med Care. 1992 Jun;30(6):473-83
– reference: 4917967 - Acta Psychiatr Scand Suppl. 1970;212:11-9
– reference: 16172203 - N Engl J Med. 2005 Sep 22;353(12):1209-23
– reference: 12404546 - Hum Psychopharmacol. 2001 Oct;16(7):495-505
– reference: 16055824 - Br J Psychiatry. 2005 Aug;187:137-42
– reference: 3616518 - Schizophr Bull. 1987;13(2):261-76
– reference: 17539698 - J Clin Psychiatry. 2007;68 Suppl 4:34-9
– reference: 16204323 - J Psychopharmacol. 2006 Jan;20(1):104-18
– reference: 16649833 - J Clin Psychiatry. 2006 Mar;67(3):453-60
– reference: 12365874 - Arch Gen Psychiatry. 2002 Oct;59(10):877-83
– reference: 14557530 - Psychiatr Serv. 2003 Oct;54(10):1407-9
– reference: 14506122 - JAMA. 2003 Sep 24;290(12):1624-32
– reference: 18156640 - Schizophr Bull. 2008 Nov;34(6):1163-71
– reference: 16626411 - Value Health. 2006 Mar-Apr;9(2):77-89
– reference: 18019047 - Br J Psychiatry Suppl. 2007 Aug;50:s64-70
– reference: 15953491 - Biol Psychiatry. 2005 Jun 15;57(12):1543-9
– reference: 12413638 - Schizophr Res. 2003 Jan 1;59(1):19-27
– reference: 19725969 - BMC Psychiatry. 2009;9:54
– reference: 15632800 - J Behav Health Serv Res. 2005 Jan-Mar;32(1):85-94
– reference: 11816864 - J Clin Psychiatry. 2001 Oct;62(10):757-71
– reference: 18794651 - J Clin Psychopharmacol. 2008 Oct;28(5):544-9
– reference: 11232749 - J Clin Psychiatry. 2001;62 Suppl 2:28-34
– reference: 2574607 - Br J Psychiatry. 1989 May;154:672-6
– reference: 16375765 - BMC Med. 2005;3:21
– reference: 7916523 - Acta Psychiatr Scand Suppl. 1994;382:11-5
– reference: 16585435 - Am J Psychiatry. 2006 Apr;163(4):611-22
– reference: 16889456 - J Clin Psychiatry. 2006 Jul;67(7):1114-23
– reference: 17329466 - Am J Psychiatry. 2007 Mar;164(3):415-27
– reference: 16585434 - Am J Psychiatry. 2006 Apr;163(4):600-10
SSID ssj0017851
Score 2.1108406
Snippet To identify patient characteristics and early changes in patients' clinical status that best predict subsequent switching of antipsychotic agents in the...
Background To identify patient characteristics and early changes in patients' clinical status that best predict subsequent switching of antipsychotic agents in...
Abstract Background: To identify patient characteristics and early changes in patients' clinical status that best predict subsequent switching of antipsychotic...
BACKGROUND: To identify patient characteristics and early changes in patients' clinical status that best predict subsequent switching of antipsychotic agents...
Abstract Background To identify patient characteristics and early changes in patients' clinical status that best predict subsequent switching of antipsychotic...
SourceID doaj
pubmedcentral
biomedcentral
proquest
gale
pubmed
crossref
SourceType Open Website
Open Access Repository
Aggregation Database
Index Database
Enrichment Source
StartPage 75
SubjectTerms Ambulatory Care
Antipsychotic Agents - administration & dosage
Antipsychotic Agents - therapeutic use
Antipsychotic drugs
Care and treatment
Clinical medicine
Cost control
Drug Administration Schedule
Female
Follow-Up Studies
Health aspects
Humans
Male
Middle Aged
Multicenter Studies as Topic - statistics & numerical data
Patient outcomes
Probability
Proportional Hazards Models
Psychiatric Status Rating Scales - statistics & numerical data
Psychiatry
Psychotropic drugs
Randomized Controlled Trials as Topic - statistics & numerical data
Schizophrenia
Schizophrenia - diagnosis
Schizophrenia - drug therapy
Schizophrenic Psychology
Severity of Illness Index
Survival Analysis
Treatment Outcome
SummonAdditionalLinks – databaseName: DOAJ Directory of Open Access Journals
  dbid: DOA
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3NaxQxFA_Sg3gR6-fYKjkIehk7k0wyCT1VsRShImhhbyHJJDhQZqW7xX_f9zLZYUMpXrwtk4SZvLzPfS-_R8g7GcAJFnaorZQDphljraMbas0wrTSw1gm8KHz5TV5cdV9XYrXX6gtrwmZ44JlwJzbIGJVsePSqU9JZCHu0dQiUpoc-JiRQsHm7YCrnD7DlfLpX1Lc1GLBVBvVplTxZnqEGwvLC4qL7dWGfEoz_XWW9Z63KSso903T-hDzOPiU9m_dySB6E6Sl5eJmz5s_Ij-83-Bv76tB1pJs_4zZVUFKg6pivYY2epjT7_AceHScKniFdytDTuv36vOfk6vzLz88XdW6mUDtwOra19D0PEuQ7iDiAUY9taPgAmrqzEfsHySADd5b3ESTYO676INuhaQJWVHPf8hfkYFpP4RWhrgGnT0jLHAQjTCsreSsb3wnseGODq8hpQVLzewbOMAhlXY6AVBk8EIMHYiAg6UVFPu4OwPiMU47tMq5NileUvLvgw7Jg96Z7p37CEy0-KD0AjjOZ48y_OK4i75EfDGoA-DBv80UGIA5iaZkzhj6nkppV5LiYCZLri-GjHUeZrDk2RqPT1XcCXkOXUVyIxXBTWN9uYB_YIZqL5v4pGhxjjb5rRV7OHLrsGaSFoRquSF_wbkGUcmQafyXgcaYRTq59_T-oeEQezYUYumbqmBxsb27DG_Dvtu5tEuW_vDxNcQ
  priority: 102
  providerName: Directory of Open Access Journals
– databaseName: Health & Medical Collection
  dbid: 7X7
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3da9UwFD_oBPFF_LbblDwI-lLXNm3a4INMcQxhIujgvoUkTVxhtPPeO_z3d05ubrlhzLdLk3DTnO-ek98BeCccOsGN7nMtRE9pRp9Lb_pcVpRW6qvSNHRR-OyHOD2vvy-aRazNWcWyyq1ODIq6nyx9Iz-SZIzauqk_X_3NqWkUJVdjB4378ICQy4ip28Ucb4W-8xHNp-zEUYl6OEdrtiDVQ3WFyQ33y8QwBfz-21p6x0ylJZQ7NunkCTyOziQ73lD_Kdxz4zN4eBbT5c_h188l_aaGOmzybPVvWIfSSYbHOcT7V4NlIb---XLHhpGhS8jm-vOwbrcw7wWcn3z7_fU0j10UcoPexjoXtuVOoGC7xvdozX3pCt6jiq61p8ZBwgnHjeatR9G1hnetE2VfFI5Kqbkt-UvYG6fRvQZmCvT2GqErg1FIJTsteCkKWzfU6kY7k8Gn5EjV1QYxQxGGdTqCpFVEEEUEURiJtE0GH7cEUDYClFOfjEsVApVO3F7wYV6w_ac7p34hiiYbCg-m5R8VZVRpJ7zvRMG97epOGI0RttSGMPlk3_o6g_fED4pEHzdmdbzBgIdDIFrquCJnsxOyyuAwmYkia5Phgy1HqagyVmpm8AzYPEoLqQpudNP1Ct-DWkPzprh7ikSPWJLTmsGrDYfO71wVKICofzNoE95NDiUdGYeLgDheScKRK_f_u-8DeLQprZB51R3C3np57d6gx7Y2b4Nc3gBW4EIu
  priority: 102
  providerName: ProQuest
– databaseName: Scholars Portal Journals: Open Access
  dbid: M48
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3da9swEBdbB2Mvpft22w09DLYXd7ZlSRallG6slEHGYAvkTUi21BmCsyUp2_773cl2GtH2ZW8h0mH5dKf7ne90R8gb4QAEc9OkRogGw4w-Vd42qSowrNQUueV4UXjyRVxMy88zPrtuBzQwcHWra4f9pKbL-dGfX39PQeFPgsJX4n0OB2wKZmqGZ4rk98kDMEsS2xlMyuuQAnahH2r73EKERYEzWGCOOV3R1fd5ZLFCYf-bx_eW_YpzK7eM1fke2R1QJj3rxeIxuee6J-ThZIijPyXfvi7xN3baoQtPV7_bdcippMDndriY1dY0BN77T3q07ShgRbpJTA902xl7z8j0_NP3jxfp0F4htQBD1qmoJXMCNN5x34CZ97nLWANnd2k8dhQSTjhmDZMedLq2rJJO5E2WOcyxZnXOnpOdbtG5l4TaDGAgF6aw4J4UqjKC5SKrS449cIyzCTmOWKp_9qU0NBa3jkdAzzTujca90eCiSJ6Qo3EDdD1ULscGGnMdPJhK3CR4tyEYn3Tn1A-4o9GCwh-L5aUelFcbJ7yvRMZ8XZWVsAZcb2UsFutTjfRlQt6iPGiUUlhYbYarDcAcrK6lzwpEoZVQRUIOo5mgy3U0fDBKlB5VQSuEYbLk8Bi6GUVCTI_r3OJqBe-BPaMZz-6eogAqK0SzCXnRS-jmnUfBT4iMZDdiSjzStT9CKfJCYYG5fP-_KQ_Ioz4fQ6VFdUh21ssr9wpg3tq-Dur7D4KiUlM
  priority: 102
  providerName: Scholars Portal
Title Predictors of switching antipsychotic medications in the treatment of schizophrenia
URI https://www.ncbi.nlm.nih.gov/pubmed/20920179
https://www.proquest.com/docview/902187454
https://www.proquest.com/docview/758833350
https://www.proquest.com/docview/954591251
http://dx.doi.org/10.1186/1471-244X-10-75
https://pubmed.ncbi.nlm.nih.gov/PMC2955631
https://doaj.org/article/ae6ff8603fc8486ba9789ab96099d7f4
Volume 10
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV3da9swED_WFsZexr7ntgt-GGwv3mzZki321IyWMkgp2wphL0KyJWoozmhS9u_3TlayqF2f9hJCJMW2Tnf3O98XwHthEQRz3WVaiI7cjC6TznSZZORW6lhhOCUKz87E6UX1bc7nf4tF3_HgF434XKD4zFAJzUli1HwH9liF9hwZ5tNfG4cB9Zj3iURhcqji848_uJPZfhUpJF-3_7503lJPcejkli46eQZPA4hMj0aqP4dHdngBj2fBTf4Sfpxf03dqpJMuXLr80698yGSK29iHvKu-Tb1ffXxjl_ZDilAw3cSd-3XbAXmv4OLk-OfX0yx0T8gMooxVJtq6tAIZ2nLXoRZ3hc3LDkVzpR01DBJW2NLosnbIsq0pm9qKostzSyHUZVuUr2F3WAz2LaQmR5THhWYGrQ8mGy3KQuRtxanFjbYmgS_RlqrfY6UMRbWr4xFkI0UEUUQQhRZIzRP4tCaAakNhcuqPcaW8gdKI-ws-bhasr_Tg1ClRNLoh_wOeMBV4U2krnGtEXrq2qRphNFrWUhuqxSe72lUJfKDzoIjl8cZaHTIXcHOoeJY6YgQyGyFZAofRTGTVNho-WJ8oFUTFUklCWXXF8TLpZpQWUvTbYBc3S3wOagld8vzhKRKRsCSwmsCb8YRunpnlyHgodxOoo7MbbUo8MvSXvtI4k1Q_rtj_L_oewJMx5EJmrDmE3dX1jX2HSG5lJrBTz-sJ7E2Pz86_T_z7EPycVc3Ec_ctzw1J2g
linkProvider BioMedCentral
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Lb9QwEB6VIgEXxJvQAj6A4BKaOIkTCyFUHtWWdiskWmlvrp3YdKUq2-5uVfGj-I_M5KW1qnLrbbW2dx3P-JuZzAvgjbCoBGe6CrUQFbkZXSidqULJya1U8dhklCg8PhCjo_THJJuswd8-F4bCKntMbIC6mpX0jnxLkjDK0yz9fHYeUtMocq72HTRartizfy7RYlt82v2G5H3L-c73w6-jsGsqEBoUvstQlHliBfK5zVyFws3FNkoqRKxUO-qjI6ywidFJ7pCTS5MUuRVxFUWWIouTMk7wd2_BbZS7Edl6-WSw75o-9131oLgQWzHifojSc0JQR3GMXkb9qScIm34BV6XCilj0QzZXZODOA7jfKa9su-W2h7Bm60dwZ9y55x_Dr59z-kwNfNjMscXldNmEajIk37TL95qWrPHnt28K2bRmqIKyId69WbcaCPgEjm7kgJ_Cej2r7XNgJkLtMhOaG7R6uCy0SGIRlWlGrXW0NQF89I5UnbUVOhTVzPZHkJUUEUQRQRRaPnkWwIeeAKrsCqJTX45T1RhGhbi64P2woP-na6d-IYp6G2q-mM1_qw4TlLbCuUJEiSuLtBBGo0UvtaEagLLKXRrAO-IHRVCDGyt1lzGBh0NFu9Q2J-W2EJIHsOnNRIgoveGNnqNUB1ELNVyoANgwSgsp6q62s4sFPge1ok6y6PopEjVwSUpyAM9aDh2emUd44RHvA8g93vUOxR-ppydNhXMuqW5d_OK_-34Nd0eH4321v3uwtwH32rAOGfJiE9aX8wv7ErXFpXnV3FEGxzcNCv8A59WAfQ
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Lb9QwEB6VIlVcEG9CC_gAgkvaxEmcWIhDS1m1lFYVUGnFxdiJDRFLttrdquKn8e-YyYsNpSfUW7S2N7Zn_M1MPA-AZ8KiEpzowtdCFHTN6HzpTOFLTtdKBQ9NQoHCh0di7yR-N07GK_Cri4UxP_I_br6byyHokxq38SH_vnVauOa4Z2IrRHj1UUiNCVHSzr_ywP48R-tt_np_F0n9nPPR209v9vy2wIBvUBAvfJGnkRXI8zZxBQo6F9ogKhC9Yu2opo6wwkZGR6lDrs5NlKVWhEUQWPIyjvIwwv-9BtdxsSkVT_iw87m_wKCa93VgUzu5NqvQPyb8V6T9ZCAg6zoCF6XFkrgcunIuycbRLbjZKrVsu-HC27Biqzuwdthe29-Fj8czeqbCPmzq2Py8XNQunAzJWrZxYGXO6nv-5gsiKyuGqinr_eDrccsOgvfg5Eo2-z6sVtPKPgRmAtQ6E6G5QWuIy0yLKBRBHidUckdb48GrwZaq0yZzh6Jc2sMW5ClFBFFEEIUWUZp4sNkRQOVtonSq1zFRtcGUiYsDXvYDujdd2nWHKDqYUP3DdPZVtVihtBXOZSKIXJ7FmTAaLX2pDeUGlEXqYg9eED8ogiA6D7qNpMDNoWReapuT0psJyT3YGPRE6MgHzesdR6kWuuZKktaXxgm-hvWtNJC88So7PZvjOqhEdZQEl3eRqJlLUp49eNBwaL9mHiAQoBzwIB3w7mBThi1V-a3OfM4l5bMLH_0XfZ_C2vHuSL3fPzpYhxuNN4j0ebYBq4vZmX2MSubCPKmPM4MvV40fvwHHgJCh
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Predictors+of+switching+antipsychotic+medications+in+the+treatment+of+schizophrenia&rft.jtitle=BMC+psychiatry&rft.au=Nyhuis%2C+Allen+W&rft.au=Faries%2C+Douglas+E&rft.au=Ascher-Svanum%2C+Haya&rft.au=Stauffer%2C+Virginia+L&rft.date=2010-09-28&rft.pub=BioMed+Central&rft.eissn=1471-244X&rft.volume=10&rft.spage=75&rft.epage=75&rft_id=info:doi/10.1186%2F1471-244X-10-75&rft_id=info%3Apmid%2F20920179&rft.externalDocID=PMC2955631
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1471-244X&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1471-244X&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1471-244X&client=summon